Literature DB >> 29593105

Medication development in opioid addiction: Meaningful clinical end points.

Nora D Volkow1, Janet Woodcock2, Wilson M Compton3, Douglas C Throckmorton2, Phil Skolnick3, Sharon Hertz2, Eric M Wargo3.   

Abstract

The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh：

Year:  2018        PMID： 29593105     DOI： 10.1126/scitranslmed.aan2595

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN： 1946-6234            Impact factor:   17.956


  19 in total

Review 1.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

2.  Development of a Cascade of Care for responding to the opioid epidemic.

Authors:  Arthur Robin Williams; Edward V Nunes; Adam Bisaga; Frances R Levin; Mark Olfson
Journal:  Am J Drug Alcohol Abuse       Date:  2019-01-24       Impact factor: 3.829

3.  The psychiatrist at the centre of the opioid crisis.

Authors:  Emiliano Rodríguez Mega
Journal:  Nature       Date:  2020-04       Impact factor: 49.962

Review 4.  A Literature Review Examining Primary Outcomes of Medication Treatment Studies for Opioid Use Disorder: What Outcome Should Be Used to Measure Opioid Treatment Success?

Authors:  Breanne E Biondi; Xiaoying Zheng; Cynthia A Frank; Ismene Petrakis; Sandra A Springer
Journal:  Am J Addict       Date:  2020-04-29

Review 5.  Toward Addiction Prediction: An Overview of Cross-Validated Predictive Modeling Findings and Considerations for Future Neuroimaging Research.

Authors:  Sarah W Yip; Brian Kiluk; Dustin Scheinost
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-11-12

6.  Response to commentaries: The quest(ion) remains in the search for a meaningful reduction-based end-point.

Authors:  Brian D Kiluk; Garrett M Fitzmaurice; Eric C Strain; Roger D Weiss
Journal:  Addiction       Date:  2018-11-25       Impact factor: 6.526

7.  Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.

Authors:  Samuel Obeng; Abdulmajeed Jali; Yi Zheng; Huiqun Wang; Kathryn L Schwienteck; Chongguang Chen; David L Stevens; Hamid I Akbarali; William L Dewey; Mathew L Banks; Lee-Yuan Liu-Chen; Dana E Selley; Yan Zhang
Journal:  ACS Chem Neurosci       Date:  2019-02-21       Impact factor: 4.418

8.  Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment.

Authors:  Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate
Journal:  Drug Alcohol Depend       Date:  2019-09-04       Impact factor: 4.492

Review 9.  Immunopharmacotherapies for Treating Opioid Use Disorder.

Authors:  Matthew L Banks; Margaret E Olson; Kim D Janda
Journal:  Trends Pharmacol Sci       Date:  2018-11       Impact factor: 14.819

10.  Changes in DSM criteria following a culturally-adapted computerized CBT for Spanish-speaking individuals with substance use disorders.

Authors:  Michelle A Silva; Yudilyn Jaramillo; Manuel Paris; Luis Añez-Nava; Tami L Frankforter; Brian D Kiluk
Journal:  J Subst Abuse Treat       Date:  2019-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.